Mackenzie Financial Corp Sells 29,211 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mackenzie Financial Corp cut its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 89.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,299 shares of the specialty pharmaceutical company's stock after selling 29,211 shares during the period. Mackenzie Financial Corp's holdings in Jazz Pharmaceuticals were worth $352,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after acquiring an additional 97 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Jazz Pharmaceuticals by 0.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company's stock valued at $1,937,000 after purchasing an additional 99 shares during the period. ProShare Advisors LLC lifted its position in Jazz Pharmaceuticals by 1.4% during the 1st quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company's stock valued at $896,000 after purchasing an additional 105 shares during the period. Pinnacle Associates Ltd. grew its position in shares of Jazz Pharmaceuticals by 1.1% during the 1st quarter. Pinnacle Associates Ltd. now owns 10,371 shares of the specialty pharmaceutical company's stock worth $1,249,000 after buying an additional 110 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after buying an additional 116 shares during the period. 89.14% of the stock is owned by institutional investors.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares of the company's stock, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on JAZZ shares. JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a research report on Monday, August 19th. HC Wainwright restated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Needham & Company LLC restated a "buy" rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. Wells Fargo & Company cut their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 1st. Finally, StockNews.com upgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, August 1st. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $173.14.

Jazz Pharmaceuticals Stock Down 0.8 %

Shares of JAZZ traded down $0.86 during mid-day trading on Monday, hitting $108.52. 418,725 shares of the company's stock were exchanged, compared to its average volume of 684,743. The company has a 50-day simple moving average of $111.02 and a 200 day simple moving average of $110.29. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. The company has a market cap of $6.84 billion, a PE ratio of 22.55, a P/E/G ratio of 1.36 and a beta of 0.57. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $137.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. On average, research analysts forecast that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.